As Part of an Exploratory Outcome, ABLi Therapeutics Used CND's Syn-One Biomarker Services to Quantify and Visualize a Decrease in Phosphorylated Alpha-Synuclein in Cutaneous Nerves of Patients in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback